Medivir to present data on additive efficacy of fostrox in combination with anti-PD1 in nonclinical tumor models at the SITC 2022 Annual Meeting
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today announces that an abstract about its lead program fostroxacitabine bralpamide (fostrox) and the potential efficacy in primary liver cancer has been accepted for presentation at the at the SITC 37th Annual Meeting, held November 10-12, 2022, in Boston, USA. The abstract, titled “Fostrox (MIV-818) in combination with anti-PD-1 shows increased efficacy in nonclinical tumour models in vivo” will be presented at the